3 ms·

With desktop gene sequencers becoming a near commodity product I’m not so sure. There are a companies that currently focus on this area specifically by leverag

With desktop gene sequencers becoming a near commodity product I’m not so sure. There are a companies that currently focus on this area specifically by leveraging the ever dropping costs and capabilities of gene sequencing by developing targeted immunotherapy solutions that can target the specific genetic makeup of a tumor from a biopsy.

User23 8y ago
This is all based on the assumption that our understanding of in vivo processes is as good as our understanding of in silico processes. It isn't. Not even close.
- amelius 8y ago
  But that's also true for mainstream/existing therapies.